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INTRODUCTION
The main reason for the recent increase in the prevalence of 
asthma may be inadequate differentiation of naïve T cells to 
Th1 and regulatory T (Treg) cells, itself induced by a decrease in 
infectious disease due to improved hygiene.
1 The human im-
mune system tends to deviate to Th2 immune reactions, which 
are suppressed by Th1 and Treg cells. When this suppression is 
inadequate, Th2 immune reactions are activated and allergic 
diseases can result (the so-called “hygiene hypothesis”). In this 
context, numerous animal studies have reported that bacille 
Calmette-Guérin (BCG) vaccination can prevent or treat asth-
ma by inhibiting airway hyperresponsiveness (AHR) and eosin-
ophilic airway inflammation through the induction of Th1/Treg 
reactions.
2-6 Our previous study indicated that BCG vaccination 
improved pulmonary function and reduced the requirement 
for therapeutic agents in patients with asthma.
7 In contrast, 
Shirtcliffe et al.
8 reported that repeated heat-inactivated BCG 
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vaccinations had no additive therapeutic effect and induced se-
vere local reactions. This may be because the effect of heat-
killed BCG in the development of airway eosinophilia is lower 
than that of live BCG,
9 and/or that the BCG Tokyo 172 strain has 
a greater therapeutic effect than other strains.
10
Because responses to drug therapy differ among individual 
patients, and BCG exerts its therapeutic effect by inhibiting Th2 
immune reactions, it is possible that BCG vaccination has a 
higher therapeutic effect in atopic patients with asthma. In-
deed, in peripheral blood mononuclear cells (PBMCs) taken 
from atopic, but not non-atopic, patients with asthma, BCG sig-
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Purpose:  Bacille Calmette-Guérin (BCG) vaccination has been reported to be an effective treatment for asthma in several animal models. This 
study investigated whether the response to BCG treatment in asthma depends on subject clinical characteristics.  Methods:  Stable asthma pa-
tients were vaccinated with BCG. One month later, alterations in pulmonary function after vaccination and their relationships with subject clinical 
characteristics were determined.  Results:  Of 149 patients with asthma, 54 (36.2%) showed a good or fair response to BCG. The ∆FEV1 after vac-
cination was significantly related to age (r=-0.348, P<0.001), peripheral blood eosinophil counts (r=0.315, P<0.001) and baseline FEV1, expressed 
as % personal best value (r=-0.474, P<0.001), but not to FEV1 % predicted value (r=-0.066, P>0.05). A good/fair response was highly prevalent in 
atopic females compared with atopic males, especially among those aged ≤50 years (90.9% vs. 40.0%, P=0.024). Age (P<0.001, odds ratios 
(OR)=0.92, confidence interval (CI)=0.88-0.96) and atopy (P<0.01, OR=4.95, CI=1.70-14.44) were significant predictors for a good/fair response in 
females. However, blood eosinophil counts (P<0.05, OR=1.18, CI=1.01-1.39) and FEV1 % best (P<0.001, OR=0.86, CI=0.79-0.94), but not age or 
atopy, were significant predictors in males. Approximately three-quarters of the males were smokers.  Conclusions:  The therapeutic effect of BCG 
in asthma may differ according to patient clinical characteristics. The greatest benefit occurred in young atopic females. Asthma activity indices, 
such as eosinophilia and FEV1 % best, were more predictive of a good/fair response in males; this may have been related to cigarette smoking.
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nificantly inhibits production of interleukin (IL)-5.
11 Allergic 
asthma is a disease characterized by eosinophilic airway in-
flammation and AHR caused by inappropriate Th2 immune re-
actions, resulting from exposure of an atopic individual to a 
sensitized allergen. For this reason, the BCG vaccine may be ef-
fective during active immune and inflammatory reactions, but 
may be ineffective during their remission due to the presence 
of only remnant remodeling with irreversible airflow obstruc-
tion. Additionally, Cui et al.
12 reported that male asthmatic mice 
produced more interferon (IFN)-γ and less IL-4/ovalbumin-
specific IgE than female asthmatic mice and that BCG treat-
ment showed a lesser therapeutic effect in male mice. More-
over, Lazarus et al.
13 suggested that the therapeutic effect of in-
haled steroids was lower in smokers than in non-smokers. 
However, to our knowledge, there is no reported study of the ef-
fect of these variables on BCG vaccination in asthmatic pa-
tients. Thus, here we evaluated the therapeutic effect of BCG 
vaccination in terms of asthmatic patients’ clinical characteris-
tics.
MATERIALS AND METHODS
In total, 153 adult patients with asthma visited the allergy clin-
ic of two university hospitals and were administered the BCG 
vaccine. A diagnosis of asthma was established in patients who 
met the following criteria: (1) presence of asthma symptoms, 
(2) improvement in forced expiratory volume in 1 second (FEV1) 
by ≥12% and ≥200 mL after asthma treatment
14 or <8 mg/mL 
of methacholine required to decrease FEV1 by 20% (PC20) in a 
methacholine bronchoprovocation test.
15 All subjects received 
asthma treatment for ≥6 months and were stable for ≥1 month 
and had 40-79% of their personal best or predicted FEV1 value, 
and a FEV1/forced vital capacity (FVC) ratio of <80%. This 
study included 22 subjects who received the BCG vaccine in 
the 2002 clinical trial
7 and 11 in the 2003 clinical trial.
16
This study was approved by the Institutional Review Boards of 
both university hospitals (IRB No. E-2008-05-036) as well as the 
Korean Food and Drug Administration. Written informed con-
sent was obtained from each patient.
The therapeutic effect of the BCG vaccine was assessed with-
out changing asthma treatment modalities. BCG vaccination 
was performed using 5.8×10
8 CFU of the Tokyo-172 strain (Ja-
pan BCG Laboratory, Tokyo, Japan). The vaccine was adminis-
tered twice at a 2-3 mm depth in the skin of the upper arm us-
ing a Japanese Needle-Planted Cylinder (Japan BCG Laborato-
ry). A good responder was defined as a subject who had an in-
crease in FEV1 of ≥12% and ≥200 mL
14 or a peak expiratory 
flow (PEF) of ≥20% and 60 L/min,
17 1 month after BCG vaccina-
tion. A fair responder was defined as a subject who had an 
FEV1 of ≥6% and ≥100 mL or a PEF of ≥10% and 30 L/min 1 
month after BCG vaccination, and a poor responder was de-
fined as a subject with any other test result 1 month after BCG 
vaccination. The degree of decrease in the present FEV1 from 
the personal best value within 1 year of BCG vaccination was 
rated on an arbitrary point scale with intervals of 6%. In cases 
where FEV1 % personal best could not be obtained, the mini-
mum PEF expressed as a percentage of the best (Min%Max)
14 
during the 1-4 weeks prior to BCG vaccination was rated on a 
point scale with intervals of 10%. Asthma activity was defined 
as a decrease in FEV1 of ≥6% or in PEF of ≥10% and the activi-
ty grade was expressed as a point.
Pulmonary function tests were performed using a computer-
ized spirometer (Spiro Analyzer ST-250, Fukuda Sanyo, Tokyo, 
Japan). Representative values for spirometry were selected from 
the best spirogram having the highest FEV1 plus FVC values 
from three or more spirograms according to the Manual of the 
Intermountain Thoracic Society.
18 The regression equation of 
Crapo et al.
19 was used for calculating predicted values of FEV1 
and FEV1/FVC ratio. Spirometry was performed at least 4 hours 
after discontinuing rapid-acting β2-agonist inhalers. Post-vacci-
nation tests were conducted within 1 hour of the time points in 
a day of the tests conducted prior to BCG vaccination.
White blood cell counts and the percentage and numbers of 
eosinophils (white blood cell count×eosinophil %) in periph-
eral blood were measured. Elevated eosinophil levels (eosino-
philia) were defined as ≥450/mm
3.
20 Additionally, serum IgE 
levels (normal <100 IU/mL) were measured using a nephe-
lometer (Behring Diagnostics GmbH, Frankfurt, Germany). 
Skin prick tests were performed using 55 common allergens, 
including Dermatophagoides farinae and D. pteronyssinus 
(Bencard, Brantford, UK). Histamine solution (1 mg/mL) and 
0.9% saline were used as positive and negative controls, respec-
tively. A positive reaction was recorded when the value of the 
averaged wheal diameter of an allergen divided by that of hista-
mine was ≥25%. IgE values specific for D. farina, D. pteronyssi-
nus, Aspergillus fumigates, Penicillium and cockroach were 
measured using a UniCAP 100
ε (Pharmacia Diagnostics, Up-
psala, Sweden). A positive value was defined as ≥0.35 kU/L. 
Atopy was defined as a positive skin prick test or serum IgE lev-
el for any allergen. Sensitization to house dust mites was de-
fined as a positive skin prick test for either of the two house dust 
mites.
Three subjects who were lost to follow-up 1 month after BCG 
vaccination, and one subject who was treated for pneumonia, 
were excluded from the study. Data are expressed as mean±
SE. In each group, comparisons between pre- and post-vacci-
nation values were made using a paired t-test. Comparisons 
between individual groups were made with Student’s t-test, 
ANOVA, post hoc analysis using the Tukey test, the chi-squared 
test, and the Fisher’s exact test, as appropriate. Correlations be-
tween individual valuables were determined using Spearman 
rank correlation coefficients. The odds ratios of good/fair re-
sponses were obtained using a logistic regression model. A P 
value of <0.05 was considered to indicate statistical significance.Choi et al.
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RESULTS
In total, 149 subjects (80 males, 69 females) were included. No 
significant difference was noted between males and females in 
age, duration of asthma, or associations with allergic rhinitis or 
paranasal sinusitis (Table 1). Peripheral blood eosinophil % was 
significantly higher in females, while the frequency of smoking, 
atopy or sensitization to house dust mites was significantly 
higher in males. Before BCG vaccination, FEV1 % predicted was 
significantly higher; however, FEV1 % personal best values were 
lower in females. Also, after BCG vaccination, FEV1/FVC ratio 
% predicted was significantly higher, but FEV1 % personal best 
values were lower in females. After BCG vaccination, activity 
grade was significantly higher in females. After BCG vaccina-
tion, Min%Max in males and FEV1/FVC ratio and Min%Max in 
females were significantly increased. A higher trend towards 
good/fair responses was observed in female than in male sub-
jects (39.1 vs. 33.8%), but this difference was not statistically sig-
nificant.
Patients with active asthma were significantly younger, and 
had a significantly lower prevalence of smoking (Table 2). Both 
before and after BCG vaccination, FEV1 % personal best and 
Min%Max were significantly lower, but the degree of improve-
ment in FEV1 after BCG vaccination was significantly higher in 
subjects with active asthma. The good/fair response rate was 
also significantly higher in subjects with active asthma (22.2%/ 
20.2% vs. 12.5%/7.5%; P<0.05). In subjects with active asthma, 
FEV1 % personal best and Min%Max were significantly in-
Table 1. Clinical characteristics of subjects with asthma and their response to 
BCG vaccination
Male (n=80) Female (n=69)
Age (yr) 58.6±1.4 56.0±1.7
Smoker* 58 (73.4%) 4 (5.8%)
Duration of asthma (yr) 12.3±1.4 13.1±1.5
Rhinitis 46 (58.2%) 40 (58.0%)
Sinusitis 38 (48.1%) 31 (44.9%)
Blood eosinophils (%) 3.51±0.34  4.82±0.56
†
Blood eosinophils >450/mm
3 9 (11.3%) 16 (23.2%)
Serum total IgE >100 IU/mL 51 (63.8%) 34 (49.3%)
Atopy
‡ 54 (69.2%) 35 (51.5%)
House dust mite sensitization* 47 (60.3%) 20 (29.9%)
Baseline
FEV1 (% predicted) 63.2±1.3  67.4±1.3
†
FEV1 (% personal best) 88.5±1.0  84.8±1.6
†
FEV1/FVC (% predicted) 81.7±1.4 84.8±1.1
Min%Max PEF 83.7±2.9 84.0±2.9
Asthma activity grade 1.35±0.14 1.65±0.19
Follow-up
FEV1 (% personal best) 89.7±0.9 84.7±1.8
†
FEV1/FVC (% predicted) 80.9±1.5  87.9±1.2
§ ll
Min%Max PEF 87.3±2.3
¶  88.5±2.1
¶
Asthma activity grade 1.14±0.12  1.65±0.20
†
∆FEV1 (mL)  54.0±21.9  83.3±36.8
∆FEV1 (%) 2.97±1.27  5.11±2.38
BCG response
Good 15 (18.8%) 14 (20.3%)
Fair 12 (15.0%) 13 (18.8%)
Poor 53 (66.3%) 42 (60.9%)
*P<0.001, 
‡P<0.05, chi-squared test.
†P<0.05, 
§P<0.001, compared with males.
llP<0.01, 
¶P<0.05, compared with baseline.
Asthma activity was graded using one point for every 6% fall in FEV1 from the 
personal best value or for every 10% fall of minimal to maximal peak expiratory 
flow (Min%Max PEF).
Table 2. Clinical characteristics of subjects with asthma classified according to 
asthma activity and their response to BCG vaccination
Activity (+) (n=109) Activity (-) (n=40)
Gender, female 53 (48.6%) 16 (40.0%)
Age (yr)  55.8±1.4* 61.7±1.6
Smoking (pack-years)  20.6±2.9
† 31.8±5.0
Duration of asthma (yr) 11.6±1.0 15.5±2.5
Rhinitis 61 (56.0%) 25 (64.1%)
Sinusitis 47 (43.1%) 22 (56.4%)
Blood eosinophils (%) 4.31±0.37  3.57±0.66
Blood eosinophils >450/mm
3 21 (19.3%) 4 (10.0%)
Serum total IgE >100 IU/mL 61 (56.0%) 24 (60.0%)
Atopy 62 (58.5%) 27 (67.5%)
House dust mite sensitization 48 (45.7%) 19 (47.5%)
Baseline
FEV1 (% predicted) 64.4±1.1  67.2±1.8
FEV1 (% personal best)  83.5±1.0
‡  96.9±0.5
FEV1/FVC (% predicted) 83.3±1.0 82.6±1.9
Min%Max PEF  77.2±2.2
‡ 95.1±0.8
Follow-up
FEV1 (% personal best)  85.8±1.2
‡ §  92.4±1.0
ll
FEV1/FVC (% predicted) 84.1±1.1 83.3±2.4
Min%Max PEF 85.4±2.0*
 ll 92.9±1.3
∆FEV1 (mL) 93.9±22.5
†  -4.0±45.3
∆FEV1 (%) 5.52±1.47
†  -0.30±2.61
BCG response
¶
Good 24 (22.0%) 5 (12.5%)
Fair 22 (20.2%) 3 (7.5%)
Poor 63 (57.8%) 32 (80.0%)
*P<0.01, 
†P<0.05, 
‡P<0.001, compared with activity (-).
§P<0.05, 
llP <0.001; compared with baseline.
¶P<0.05, chi-squared test.
Asthma activity was defined as ≥1 point and graded using 1 point for every 6% 
fall in FEV1 from the personal best value or every 10% fall of minimal to maxi-
mal peak expiratory flow (Min%Max PEF).Personal Factors and BCG in Asthma
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creased after BCG vaccination; however, in those with inactive 
asthma, FEV1 % personal best was significantly decreased.
There was an inverse correlation between age and degree of 
FEV1 improvement after BCG treatment (∆FEV1), but there 
was a positive correlation between peripheral blood eosinophil 
% and ∆FEV1 (Fig. 1). FEV1 % personal best, but not FEV1 % 
predicted, was significantly related to ∆FEV1 (Fig. 2).
The rate of good/fair responses was significantly higher in 
subjects with eosinophilia (≥450/mm
3)
20 (40.0%/28.0% vs. 
15.3%/14.5%, χ2=13.5; P=0.001). Good or fair response rates 
each occurred in 21.3% of atopic, but only 15.8% and 10.5% of 
non-atopic, subjects. The 42.7% good+fair response rate in 
atopic subjects was significantly higher than the 26.3% rate in 
non-atopic subjects (P=0.045; Fig. 3). Although atopic and 
non-atopic male subjects did not differ in their good+fair re-
sponse rate (33.3% each), atopic female subjects had a signifi-
cantly higher rate of good+fair responses (57.1% vs. 21.2%; 
P<0.01). Among atopic subjects, the good+fair response rate in 
females was significantly higher than in males (57.1% vs. 33.3%; 
P=0.027). When the analysis was limited to subjects younger 
than 50 years old, 10/11 (90.9%) females showed a good or fair 
response compared with 4/10 (40.0%) males (P=0.024; Fig. 3).
Good responders to BCG vaccination were significantly young-
er and had a significantly higher blood eosinophil % than poor 
responders (Table 3). The distribution of subjects with eosino-
philia differed significantly depending upon responses to BCG 
vaccination, but the distribution of subjects with positive reac-
tions to atopy markers did not. FEV1 % predicted was signifi-
cantly lower in good than that in fair responders, and FEV1 % 
personal best was significantly lower in good than that in fair/
poor responders. The FEV1/FVC ratio was significantly higher 
in good than in poor responders after BCG vaccination. The 
grade of asthma activity before BCG vaccination was signifi-
cantly higher in good than in poor responders, but this was re-
versed after BCG vaccination. Compared with baseline, lung 
function and asthma activity grade were improved after BCG 
vaccination in good/fair responders, with the exception of 
Min%/Max in fair responders. However, FEV1 % personal best 
was significantly decreased and asthma activity grade increased 
significantly after BCG vaccination in poor responders.
Crude odds ratios for good/fair responses were significant in 
terms of age, blood eosinophil %, atopy, FEV1 % personal best, 
and asthma activity grade (Table 4). In males, blood eosinophil 
%, FEV1 % personal best, and asthma activity grade were signif-
icant and, in females, age, blood eosinophil %, atopy and FEV1 
% personal best were significant. No adjusted odds ratio was 
Fig. 1. Relationship between the change in forced expiratory volume in 1 sec 
(FEV1) after BCG vaccination and age (left panel) or peripheral blood eosinophil 
% (right panel).
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Fig. 2. Relationship between the change in forced expiratory volume in 1 sec 
(FEV1) after BCG vaccination and baseline FEV1 expressed as % predicted val-
ue (left panel) or % personal best value (right panel).
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Fig. 3. Proportion of subjects who showed a good or fair response to BCG vac-
cination to total subjects among asthma patients with or without atopy (left 
panel) and in ≤50 year-old males and females with atopic asthma (right pan-
el). Good or fair response: ∆forced expiratory volume in 1 sec (FEV1) ≥6% and 
100 mL or ∆peak expiratory flow (PEF) ≥10% and 30 L/min; atopy: wheal size 
of allergen >25% of that of histamine or allergen-specific IgE ≥0.35 kU/L 
(UniCAP).
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significant in total or for either gender. Similar results were ob-
tained in subjects with active asthma; however, in females, age, 
blood eosinophil % and atopy were significant, and adjusted 
odds ratios showed that age and atopy were significant.
DISCUSSION
In this study, BCG vaccination was effective in young female 
subjects. In elderly patients, lymphocyte proliferation and de-
layed hypersensitivity by antigen stimulation are decreased,
21 
which may lead to a decreased effect of BCG vaccination. Our 
Table 3. Clinical characteristics of subjects with asthma classified according to their response to BCG vaccination
Good responder (n=29) Fair responder (n=25) Poor responder (n=95)
Gender, female 14 (48.3%) 13 (52.0%) 42 (44.2%)
Age (yr) 49.3±2.2* 55.2±3.1 60.4±1.3
Smoker  13 (44.8%) 8 (33.3%) 41 (43.2%)
Duration of asthma (yr) 12.1±1.9 11.6±2.2 13.0±1.4
Rhinitis 14 (48.3%) 17 (68.0%) 55 (58.5%)
Sinusitis 10 (34.5%) 15 (60.0%) 44 (46.8%)
Blood eosinophils (%) 5.96±0.88
† 5.05±0.71 3.30±0.36
Blood eosinophils >450/mm
3 ‡ 10 (34.5%) 7 (28.0%) 8 (8.4%)
Serum total IgE >100 IU/mL 17 (58.6%) 17 (68.0%) 51 (53.7%)
Atopy 19 (67.9%) 19 (76.0%) 51 (54.8%)
House dust mite sensitization 10 (35.7%) 12 (48.0%) 45 (48.6%)
Baseline
FEV1 (% predicted) 61.3±2.5
§ 69.3±2.2 65.2±1.1
FEV1 (% personal best) 73.9±3.8* 
ll 85.1±1.3 89.1±0.9
FEV1/FVC (% predicted) 78.9±2.3 84.3±1.9 84.0±1.1
Min%Max PEF 82.9±2.7 81.7±4.3 88.8±4.0
Asthma activity grade 2.14±0.32
† 1.68±0.23 1.24±0.14
Follow-up
FEV1 (% personal best) 92.7±3.0
¶ 92.2±1.3
¶ 85.9±1.1
¶
FEV1/FVC (% predicted) 86.7±2.0** 
‡‡ 86.7±2.5
‡‡ 82.0±1.4
Min%Max PEF 88.5±2.2
‡‡ 85.6±3.1 90.6±2.2
Asthma activity grade 0.83±0.22
¶ ** 0.88±0.18
¶ ** 1.67±0.15
¶
*P<0.001, 
†P<0.01, **P<0.05, compared with poor responder.
‡P<0.05, chi-squared test.
§P<0.05, 
llP<0.01, compared with fair responder.
¶P<0.001, 
††P<0.05, 
‡‡P<0.01, compared with baseline.
Asthma activity was graded using one point for every 6% fall in FEV1 from the personal best value or every 10% fall of minimal to maximal peak expiratory flow 
(Min%Max PEF).
Table 4. Crude odds ratios (95% confidence interval) for a good/fair response to BCG vaccination
Total Male Female
Gender, female 1.262 (0.646-2.465)
Age (yr) 0.952 (0.926-0.979)* 0.981 (0.946-1.019)  0.921 (0.880-0.964)*
Smoker  0.864 (0.436-1.713)
Blood eosinophils (%) 1.165 (1.058-1.284)
† 1.184 (1.006-1.394)
‡  1.152 (1.020-1.302)
‡
Serum total IgE (IU/mL) 1.255 (0.705-2.233)
Atopy 2.086 (1.012-4.303)
‡ 1.000 (0.361-2.773)  4.952 (1.699-14.44)
†
Baseline FEV1 (% best) 0.908 (0.862-0.956)* 0.861 (0.788-0.941)*  0.931 (0.875-0.991)
‡
Asthma activity grade 1.415 (1.104-1.814)
† 2.144 (1.363-3.373)* 1.110 (0.821-1.502)
*P<0.001, 
†P<0.01, 
‡P<0.05.Personal Factors and BCG in Asthma
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previous studies showed that FEV1 was increased, from 2.16 L 
to 2.43 L (12.5%) in middle-aged subjects (mean age 44.9 years)
7 
and from 2.14 L to 2.38 L (11.2%) in those with a mean age of 
54.2 years
16 1 month after BCG vaccination. However, in this 
study, FEV1 was increased by only 5.5% in subjects with active 
asthma, which may be explained by their greater age (55.8 
years). In elderly subjects, β-adrenergic receptor affinity, ade-
nyl cyclase activity
22 and the number of glucocorticoid recep-
tors
23 are reduced. Since treatment outcomes were analyzed af-
ter add-on BCG vaccination without placebo controls, con-
comitant therapy including steroids and its age-dependency 
may have impacted the data.
BCG vaccination was effective in atopic allergy associated 
with Th2 reactions. BCG vaccination suppresses the develop-
ment of asthma through Th1/Treg cell reactions in animal 
models of atopic asthma induced by sensitization and provoca-
tion with ovalbumin
2-6,10,12,24 or D. farina,
24 as well as IL-5 pro-
duction in PBMCs of atopic patients with asthma.
11 The rela-
tively high prevalence of atopic asthma in females, particularly 
those of child-bearing age, is likely due to elevated female sex 
hormone levels.
25 Thus, BCG vaccination is thought to be effec-
tive in female patients with active atopic asthma.
Three-quarters of male, but only 5.8% of female, subjects were 
past or current smokers. This may have affected both clinical 
characteristics and the therapeutic effect of BCG vaccination. 
The fact that FEV1 and FEV1/FVC ratio expressed as % predict-
ed were lower in males may be explained by smoking-related 
irreversible airflow obstruction. The inactive asthma group 
contained a higher proportion of smokers, and male subjects 
showed a higher FEV1 % personal best and a lower asthma ac-
tivity. It is thus conceivable that male subjects received BCG 
vaccination due not to inadequate control of asthma, but to 
lower lung function induced by smoking. Despite the higher 
house dust mite sensitization rate and the higher prevalence of 
atopy in males, the poor effect of BCG vaccination on their 
FEV1/FVC ratio in males, compared with females, may be at-
tributed to smoking. Because smoking increases total serum 
IgE, facilitates allergic sensitization and induces allergic diseas-
es,
26,27 males show a higher rate of sensitization to house dust 
mites and prevalence of atopy. However, Lazarus et al.
13 dem-
onstrated that smoking decreased the effect of steroids. Smok-
ing down-regulates histone deacetylase activity, increases tu-
mor necrosis factor-α production, decreases the proportion of 
glucocorticoid isoform-α (GR-α) relative to GR-β, and promotes 
the synthesis of cysteinyl leukotrienes.
13 The therapeutic effect 
of BCG vaccination may also be influenced through such 
mechanisms.
In males, the factors that affected the therapeutic effect of 
BCG vaccination included blood eosinophil %, FEV1 and asth-
ma activity, but not age or atopic allergy. This may be because 
many male subjects, even though they were enrolled due to 
their low lung function, might have only airway remodeling 
remnants after suppression of eosinophilic airway inflamma-
tion because those who had received asthma treatments for ≥6 
months and had been stable for ≥1 month, were selected. Al-
ternatively, such subjects may have been suffering smoking-re-
lated irreversible airflow obstruction and low asthma activity. 
Thus, in such individuals only a small proportion of disease 
components were reversible. Even if subjects were more highly 
sensitized to allergens, the effect of BCG may have been lower 
in those whose condition was in a drug-induced stable state. 
However, the therapeutic effect of BCG vaccination was signifi-
cantly related to asthma activity grade and markers for asthma 
activity, such as blood eosinophil % and personal best FEV1 %, 
but not to predicted FEV1 %. When only male subjects with ac-
tive asthma were included, the above markers for asthma activ-
ity, but not age and atopy, were significant factors affecting the 
likelihood of a good/fair response to BCG vaccination. Because 
the effect of smoking can obscure the influence of age and ato-
py, further studies with non-smokers are needed to evaluate 
the latter. Asthma occurs more frequently and the response to 
montelukast is better in males during childhood, but this trend 
is reversed after adolescence by the effects of female sex hor-
mones.
28 This was interpreted as indicating that asthma was 
more active during childhood in boys, but in girls after adoles-
cence. Similarly, in this study BCG vaccination was more effec-
tive in subjects with active asthma.
Because vaccination is more effective in female mice,
12 it seems 
likely that BCG vaccination may also be more effective in fe-
male subjects. In this study, female subjects showed a higher, 
but non-significant, trend towards good/fair responses. Al-
though the therapeutic effect of BCG vaccination was related to 
the prevalence of atopy and house dust mite sensitization in fe-
males, the lower prevalence of atopy and house dust mite sen-
sitization rate in female subjects might have caused the lack of 
statistical significance. When only atopic patients were includ-
ed, good/fair responses were more frequent in females than in 
males (57.1 vs. 33.3%). Because atopic asthma occurs more fre-
quently in females of child-bearing age,
25 when only female 
subjects aged <50 years were included, 10/11 (90.9%) versus 
40.0% of males responded to BCG vaccination. The one female 
who did not respond to BCG vaccination was 46 years old and 
may have been going through menopause. Thus, BCG vaccina-
tion seems to be effective for treatment of atopic asthma in pre-
menopausal females. Males have a higher serum level of dehy-
droepiandrosterone sulfate (DHEA-S), and an increased IFN-
γ:IL-5 ratio induced by DHEA administration is inversely corre-
lated with DHEA-S concentration.
29 Thus, it is conceivable that 
males may adapt to increased DHEA and other androgen con-
centrations, which decreases the Th1-induced therapeutic ef-
fect of BCG vaccination.
FEV1 was significantly decreased in subjects with inactive 
asthma after BCG vaccination, and asthma activity grade in-
creased in poor responders. Even without BCG vaccination, Choi et al.
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subjects with stable asthma who had no decrease in personal 
best FEV1 % may have decreased lung function after 1 month 
because FEV1 could not increase above the personal best val-
ue. Similarly, subjects with a very low grade of activity would 
naturally show increased activity over time. Such a phenome-
non of regression towards the mean
30 in statistics may thus ex-
plain the above result. However, BCG infection induces neutro-
philia,
10,31 and so we cannot exclude the possibility that it may 
also lead to aggravation of asthma even if only in a transient 
fashion.
The grade of asthma activity used in this study was arbitrarily 
defined and so its validity needed to be confirmed. Because rel-
atively few subjects responded to BCG vaccination, we evaluat-
ed therapeutic responses by changes in the 50% values of re-
versibility of airflow obstruction.
14 Such a small change may oc-
cur in the absence of any treatment. Thus, further work with a 
larger sample size and placebo control is needed. A clinically 
significant wheal reaction is typically defined as >3+,
32 but we 
defined a positive reaction as >1+ (25% of the wheal reaction 
produced by histamine) because the response tended to be 
lower due to the higher mean age of subjects. Thus, further in-
vestigations using different criteria for skin reactions are war-
ranted.
Taken together, age and atopy were the most important fac-
tors influencing the therapeutic effect of BCG vaccination on 
asthma in females and BCG vaccination was most effective in 
pre-menopausal females with atopic asthma. In men, asthma 
activity markers, such as peripheral blood eosinophil % and 
personal best FEV1 %, were the major factors, and the high pro-
portion of smokers among male subjects influenced the out-
comes. Thus, physicians should consider gender, age, atopy, 
asthma activity, and smoking to achieve better outcomes from 
using BCG vaccination as a treatment for asthma.
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